VANI - NASDAQ
Vivani Medical, Inc.
$1.28
+0.39%Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
At a Glance
Live Snapshotvani
Cash and Cash Equivalents
Last Annual Value
16.23M
3-Year CAGR
-29%
5-Year CAGR
51%
10-Year CAGR
%
Vivani Medical, Inc. Competitors Analysis of Cash and Cash Equivalents
| Company | Cash and Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Vivani Medical, Inc. NASDAQ:VANI | 16.23M | -7.7% | 49.4% | 4.1% | |
 Microbot Medical Inc. NASDAQ:MBOT | 3.91M | 16.6% | -21.9% | 3.7% | |
 Clene Inc. NASDAQ:CLNN | 5.19M | -43.5% | -36.5% | N/A | |
 CervoMed Inc. NASDAQ:CRVO | 9.00M | 4.9% | -24.8% | 19.2% | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 10.66M | 8.8% | -23.9% | 41.1% | |
 Pulmonx Corporation NASDAQ:LUNG | 70.01M | -5.7% | -14.0% | N/A | |
 Spectral AI, Inc. NASDAQ:MDAI | 15.39M | 47.6% | -0.9% | N/A | |
 XBiotech Inc. NASDAQ:XBIT | 125.55M | -14.4% | -11.9% | 13.8% | |
 Immix Biopharma, Inc. NASDAQ:IMMX | 93.93M | 75.1% | 39.7% | N/A | |
 FONAR Corporation NASDAQ:FONR | 56.33M | 3.2% | 4.8% | 20.8% | |
 Quipt Home Medical Corp. NASDAQ:QIPT | 12.92M | -9.1% | -17.9% | 9.6% |
Vivani Medical, Inc. Fair Value Envelope
Related Guides
Continue your VANI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.